Management
Our team of seasoned industry experts explores the world of water-free therapies to develop best-in-class ocular therapies. We expand into other eye care indications and topical therapeutics spaces.
Since December 2019, Novaliq has a strategic cooperation with Bausch + Lomb. Bausch has received exclusive rights to develop, manufacture and commercialize NOV03 (perfluorohexyloctane) in USA and Canada.
In September 2022 acceptance of filing of a New Drug Application (NDA) by the U.S. Food and Drug Administration (FDA) was announced for NOV03 for the proposed indication of treating the signs and symptoms of dry eye disease (DED) associated with Meibomian gland dysfunction (MGD).
In China, Novaliq has a strategic cooperation with Jiangsu Hengrui Pharmaceuticals since November 2019.
Hengrui has received exclusive rights to develop, manufacture and commercialize NOV03 and CyclASol® for the treatment of dry eye disease in China.
In April 2019, Novaliq has founded Betaliq Inc., Tampa, USA in collaboration with BLP Management Group, LLC. Betaliq develops ophthalmic beta-blockers using Novaliq’s proprietary EyeSol® water-free technology.
The company completed successfully a phase 2 trial in patients diagnosed with increased intraocular pressure due to hypertension or open-angle glaucoma in the USA in 2022. Betaliq plans to enter phase 3 with BTQ-1902 (timolol in EyeSol®) beginning in 1H 2023.
Our journey as a company started by developing a first-in-class, preservative-free topical eye treatment and tear film stabilizer based on perfluorohexyloctane.
These novel water-free products are clinically validated by significant improvement in signs and symptoms in patients with evaporative dry eye disease and Meibomian gland disfunction MGD in a number of clinical trials. This new class of water-free products was initially CE certified in 2014.
Today Perfluorohexyloctane containing eye drops are successfully commercialized in Australia/New Zealand by AFT Pharmaceuticals and in Europe by Ursapharm.
Ursapharm Arzneimittel is one of the leading EU ophthalmic players.
In October 2015, EvoTears® (perfluorohexyloctane) entered the EU market. EvoTears® has been successfully launched in 17 European countries incl Germany, France, UK, Spain, Italy, Benelux, Poland and Switzerland.
In some countries the product is also known under other brand names: HYLO LIPID® (France), Hycosan Shield® (UK).
In January 2020 the novel product EvoTears® OMEGA with algae derived omega-3 to alleviate irritated eyes and lid margins has been launched in Germany and other countries in Europe.
AFT Pharmaceuticals is a New Zealand-based pharmaceutical company listed in ASX and NZX, and Novaliq’s partner for the commercialization of NovaTears® (perfluorohexyloctane) and NovaTears+Omega-3 in Australia and New Zealand.
In 2020, AFT moved from the number three to number two position in the lubricating eyecare category in Australia with sales growth from the NovaTears® range contributing to its growth.
In Australia NovaTears® is PBS listed since September 2018. The PBS Schedule lists all of the medicines available to be dispensed to patients at a government-subsidized price.
Academic partners
Novaliq collaborates with leading scientific partners
Prof. Dr. med. Claus Cursiefen and Prof. Dr. med. Philipp Steven in the field of ophthalmic drug delivery for the anterior segment of the eye with special focus on dry eye disease.
Prof. Heping Xu, MD, PhD, in the field of retina diseases.
Dr. Ilva Rupenthal in the field of drug delivery technologies and ocular therapeutics.
Prof. Dr. med. Johannes Wohlrab in the field of penetration and dermatology.
Prof. Dr. Wolfgang Frieß in the field of protein formulation.
Prof. Gordon Tiddy and Dr. Robin Curtis in the field of basic research in formulation sciences.